Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefixime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | APAF1 | O14727 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | PLCG1 | P19174 | 1/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 1/20 | 1.00 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 1.00 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.98 |
| ▸ | MMP2 | P08253 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.79 |
| ▸ | CNR1 | P21554 | 1/20 | 0.79 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | PPARG | P37231 | 2/20 | 0.61 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.61 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefixime SCHEMBL3553111 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL4812946 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL17131963 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL16072825 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL9483204 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL12374914 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL3553107 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL4812929 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL9483213 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL28541257 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2688 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4434588-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-3452124-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-10-08 | — | — | EP | claimed |
| EP-3452123-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-09-24 | — | — | EP | claimed |
| EP-3965808-B1 | USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT | UNIV YEDITEPE (TR) | 2025-09-03 | — | — | EP | claimed |
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | RECREO PHARMACEUTICALS LLC (US) | 2025-07-29 | — | — | US | claimed |
| EP-3230500-B1 | METHODS OF ORIENTING MULTIFILAMENT YARN AND MONOFILAMENTS OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF | TEPHA INC (US) | 2025-06-18 | — | — | EP | claimed |
| EP-3711797-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2025-02-12 | — | — | EP | claimed |
| EP-4125905-B1 | REGIMEN FOR TREATING A NEISSERIA GONORRHOEAE INFECTION WITH GEPOTIDACIN | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-12-25 | — | — | EP | claimed |
| EP-3955930-B1 | METHODS FOR PREDICTING NEISSERIA SPP. SUSCEPTIBILITY TO CEFIXIME | THE REGENTS OF UNIV OF CALIFORNIA (US) | 2024-11-06 | — | — | EP | claimed |
| WO-2000017212-A1 | ORGANOPHOSPHOROUS COMPOUNDS AND USE THEREOF | JOMAA HASSAN (DE) | 2000-03-30 | — | — | WO | claimed |
| WO-2000016757-A2 | USE OF ORGANOPHOSPHOROUS COMPOUNDS FOR PRODUCING MEDICAMENTS FOR THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF INFECTIONS OR AS A FUNGICIDE, BACTERICIDE OR HERBICIDE FOR PLANTS | JOMAA PHARMAKA GMBH (DE) | 2000-03-30 | — | — | WO | claimed |
| EP-0685232-B1 | Cefixim formulation | MERCK PATENT GMBH (DE) | 2000-03-22 | — | — | EP | claimed |
| WO-2000004031-A1 | PHOSPHOROUS ORGANIC COMPOUNDS AND THEIR USE | JOMAA HASSAN (DE) | 2000-01-27 | — | — | WO | claimed |
| EP-0971691-A2 | COMBINATION PREPARATION FOR ORALLY ADMINISTERED ANTIBIOTICS | Lindopharm Gmbh (DE) | 2000-01-19 | — | — | EP | claimed |
| WO-1999052515-A2 | USE OF ORGANOPHOSPHORIC COMPOUNDS FOR THE THERAPEUTIC AND PREVENTATIVE TREATMENT OF INFECTIONS | HASSAN JOMAA (DE) | 1999-10-21 | — | — | WO | claimed |
| WO-1998036732-A2 | COMBINATION PREPARATION FOR ORALLY ADMINISTERED ANTIBIOTICS | LINDOPHARM GMBH (DE) | 1998-08-27 | — | — | WO | claimed |
| EP-0685232-A2 | Cefixim formulation | MERCK PATENT GmbH (DE) | 1995-12-06 | — | — | EP | claimed |
| EP-0603755-A2 | Cephalosporin salts and processes for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-06-29 | — | — | EP | claimed |
| EP-0388510-A1 | Pharmaceutical compositions and their use in the prophylaxis or the treatment of bacterial infectious diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-09-26 | — | — | EP | claimed |